Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Feb 11;19(1):65.
doi: 10.1186/s12884-019-2209-7.

A qualitative study on stakeholders' views on the participation of pregnant women in the APOSTEL VI study: a low-risk obstetrical RCT

Affiliations

A qualitative study on stakeholders' views on the participation of pregnant women in the APOSTEL VI study: a low-risk obstetrical RCT

Indira S E van der Zande et al. BMC Pregnancy Childbirth. .

Abstract

Background: Bioethicists argue that inclusion of pregnant women in clinical research should be more routine to increase the evidence-base for pregnant women and foetuses. Yet, it is unknown whether pregnant women and others directly involved are willing to be routinely included. Therefore, we first need to establish what these stakeholders think about research participation in regular pregnancy-related research. However, studies on their views are scarce. In our study, we piggy-backed on a relatively conventional RCT, the APOSTEL VI study, to identify the views of stakeholders on inclusion of pregnant women in this study.

Methods: We conducted a prospective qualitative study using 35 in-depth semi-structured interviews and one focus group. We interviewed pregnant women (n = 14) recruited for the APOSTEL VI study, in addition to healthcare professionals (n = 14), Research Ethics Committee members (RECs) (n = 5) and regulators (n = 7) involved in clinical research in pregnant women.

Results: Three themes characterise stakeholders' views on inclusion of pregnant women in the APOSTEL VI study. Additionally, one theme characterises stakeholders' interest in inclusion of pregnant women in clinical research in general. First, pregnant women participate in the APOSTEL VI study for potential individual benefit and secondarily for altruistic motives, contrary to hypothetical studies. Second, a gatekeeping tendency hampers recruitment of pregnant women who might be eligible and willing, and questions about pregnant women's decisional capacities surface. Third, healthcare professionals sometimes use the counselling conversation to steer pregnant women in a direction. Fourth, all stakeholders are hesitant about inclusion of pregnant women in clinical research in general due to a protective sentiment.

Conclusions: Pregnant women are willing to participate in the APOSTEL VI study for potential individual benefit and altruistic motives. However, an underlying protective sentiment, resulting in gatekeeping and directive counselling, sometimes hampers recruitment in the APOSTEL VI study as well as in clinical research in general. While bioethicists claim that inclusion of pregnant women should be customary, our study indicates that healthcare professionals, regulators, RECs and pregnant women themselves are not necessarily interested in inclusion. Advancing the situation and increasing the evidence-base for pregnant women and foetuses may require additional measures such as investing in the recruitment and feasibility of RCTs and stimulating pregnant women's decisional capacities.

Keywords: Inclusion in research; Obstetrics and Gynaecology; Pregnant women; Recruitment; Research ethics; Willingness.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

The Research Ethics Committee of the UMC Utrecht (Medische Ethische Toetsingscommissie UMC Utrecht) assessed the qualitative research proposal and issued a waiver for the project (WAG/om/15/006748). Verbal informed consent was obtained in the case of healthcare professionals, Research Ethics Committee members and regulators. For all participants, verbal informed consent was documented in the recorded interviews. In the case of pregnant women, both verbal and written informed consent was obtained. The ethics committee formally approved the written consent form and procedure, which entailed a detailed description of the interview process after which both the participant and the researcher signed the informed consent form.

Consent for publication

N/A

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Flowchart of Inclusion

Similar articles

Cited by

References

    1. Lyerly AD, Little MO, Faden R. The second wave: toward responsible inclusion of pregnant women in research. Int J Fem Approaches Bioeth. 2008;1:5–22. doi: 10.3138/ijfab.1.2.5. - DOI - PMC - PubMed
    1. Little M, Lyerly A, Faden R. Pregnant women and medical research: a moral imperative. Bioethica Forum. 2009;2:60–65.
    1. Baylis F. Pregnant women deserve better. Nature. 2010;465:689–690. doi: 10.1038/465689a. - DOI - PubMed
    1. Haas DM, Gallauresi B, Shields K, Zeitlin D, Clark SM, Hebert MF, et al. Pharmacotherapy and pregnancy: highlights from the third international conference for individualized pharmacotherapy in pregnancy. Clin Transl Sci. 2011;4:204–209. doi: 10.1111/j.1752-8062.2011.00280.x. - DOI - PMC - PubMed
    1. EMA (European Medicines Agency) Guideline of the exposure to medicinal products during pregnancy: need for post-authorisation data. 2005.

Grants and funding

LinkOut - more resources